Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 11:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 158 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Infliximab Clear all
Recruiting No phase listed Observational Accepts healthy volunteers

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

NCT04278404
View directory record Official record
Conditions
Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
Interventions
The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Duke University
Other
Eligibility
0 Years to 20 Years
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
49
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 16, 2026, 11:34 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Impact of Breathing Interventions on Stress Markers

NCT05825846
View directory record Official record
Conditions
Physiological Stress
Interventions
Virtual- reality active shooter drill
Device
Lead sponsor
Texas State University
Other
Eligibility
18 Years to 39 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Marcos, Texas
Source: ClinicalTrials.gov public record
Updated Apr 25, 2023 · Synced Oct 16, 2026, 11:34 PM EDT
Terminated Phase 4 Interventional Results available

An Efficacy and Safety Study of Infliximab Dose Escalation in Pediatric Participants With Inflammatory Bowel Disease

NCT02566889
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
Infliximab
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
6 Years to 16 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
29
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 16, 2026, 11:34 PM EDT
Completed Phase 3 Interventional Results available

Demonstrate Noninferiority in Efficacy and to Assess Safety of CT-P13 in Patients With Active Crohn's Disease

NCT02096861
View directory record Official record
Conditions
Crohn's Disease
Interventions
CT-P13, Remicade
Biological
Lead sponsor
Celltrion
Industry
Eligibility
18 Years to 75 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 9, 2018 · Synced Oct 16, 2026, 11:34 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Single-Dose Study of MT-201 and Concomitant Infliximab in Healthy Participants

NCT07776782
View directory record Official record
Conditions
Healthy Volunteer
Interventions
MT-201
Drug
Lead sponsor
Mirador Therapeutics, Inc.
Industry
Eligibility
19 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 16, 2026, 11:34 PM EDT
Terminated Phase 3 Interventional Results available

A Golimumab Phase 3b, Multicenter, Assessment of Intravenous Efficacy in Rheumatoid Arthritis Subjects Who Have Diminished Disease Control Despite Treatment With Infliximab (REMICADE®)

NCT01962974
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Golimumab 2 mg/kg IV
Biological
Lead sponsor
Janssen Biotech, Inc.
Industry
Eligibility
18 Years to 76 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
47
States / cities
Birmingham, Alabama • Huntsville, Alabama • Peoria, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Oct 16, 2026, 11:34 PM EDT
Completed No phase listed Observational Results available

Observational, Real World Study Of Inflectra In Patients With Inflammatory Bowel Disease

NCT03801928
View directory record Official record
Conditions
Inflammatory Bowel Disease (IBD), Crohn's Disease (CD), Ulcerative Colitis (UC)
Interventions
Inflectra
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
11
States / cities
San Diego, California • Hamden, Connecticut • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2021 · Synced Oct 16, 2026, 11:34 PM EDT
Recruiting Phase 4 Interventional

Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease

NCT05781152
View directory record Official record
Conditions
Crohn Disease
Interventions
Anti-TNF therapy
Drug
Lead sponsor
Connecticut Children's Medical Center
Other
Eligibility
6 Years to 17 Years
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
22
States / cities
Phoenix, Arizona • Los Angeles, California • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 16, 2026, 11:34 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Cross Sectional Study of Vaccine Antibody Response in Inflammatory Bowel Disease Patients

NCT02434133
View directory record Official record
Conditions
Inflammatory Bowel Disease (IBD)
Interventions
Blood Draw/Data Collection
Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 65 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 27, 2018 · Synced Oct 16, 2026, 11:34 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Diagnosis of Intestinal Motility by Image Analysis Using Capsule Endoscopy

NCT01085513
View directory record Official record
Conditions
Intestinal Abnormalities
Interventions
PillCam SB2
Device
Lead sponsor
Medtronic - MITG
Industry
Eligibility
16 Years to 80 Years
Enrollment
143 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 22, 2020 · Synced Oct 16, 2026, 11:34 PM EDT
Withdrawn Phase 2 Interventional

Medical Treatment of Colitis in Patients With Hermansky-Pudlak Syndrome

NCT00514982
View directory record Official record
Conditions
Hermanski-Pudlak Syndrome, Colitis, Cytokines, Lymphocytes, Drug Evaluation
Interventions
Mesalamine, Infliximab, Corticosteroids, 6-Mercaptopurine, Tacrolimus, Adalimumab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 16, 2026, 11:34 PM EDT
Completed No phase listed Observational

Cytokines and Genes in Therapeutic Response in Crohn's Disease

NCT03266471
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
Baseline blood sample, Baseline intestinal biopsies, Crohn's disease activity index (CDAI), Post treatment blood sample, Post treatment intestinal biopsies, Baseline stool sample, Post treatment stool sample
Diagnostic Test · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 14, 2023 · Synced Oct 16, 2026, 11:34 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study of NI-071 in Participants With Rheumatoid Arthritis (RADIANCE)

NCT02990806
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
NI-071, Remicade
Drug
Lead sponsor
Nichi-Iko Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
683 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
75
States / cities
Little Rock, Arkansas • Los Angeles, California • Ventura, California + 55 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Oct 16, 2026, 11:34 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of Infliximab(REMICADE ) in Pediatric Patients With Moderately to SeverelyActive Ulcerative Colitis

NCT00336492
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
infliximab
Biological
Lead sponsor
Centocor, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
18
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2013 · Synced Oct 16, 2026, 11:34 PM EDT
Completed Phase 4 Interventional Results available

A Study of Infliximab for Treatment Resistant Major Depression

NCT00463580
View directory record Official record
Conditions
Depression
Interventions
Infliximab, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
25 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 8, 2025 · Synced Oct 16, 2026, 11:34 PM EDT
Completed Phase 3 Interventional Results available

Infliximab Plus Intravenous Immunoglobulin for the Primary Treatment of Kawasaki Disease

NCT00760435
View directory record Official record
Conditions
Kawasaki Disease
Interventions
Infliximab, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
4 Weeks to 17 Years
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
2
States / cities
La Jolla, California • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 24, 2014 · Synced Oct 16, 2026, 11:34 PM EDT
Completed No phase listed Observational

A Study of Comparing Rates of Dementia and Alzheimer's Disease in Participants Initiating Methotrexate Versus Those Initiating Anti-tumor Necrosis Factor (TNF)-Alpha Therapy

NCT04571697
View directory record Official record
Conditions
Dementia, Alzheimer Disease
Interventions
Methotrexate, Anti-TNF
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
34,647 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Titusville, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 16, 2026, 11:34 PM EDT
Active, not recruiting No phase listed Observational

Psoriasis Longitudinal Assessment and Registry

NCT00508547
View directory record Official record
Conditions
Psoriasis
Interventions
Not listed
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
20,167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2030
U.S. locations
167
States / cities
Birmingham, Alabama • Florence, Alabama • Huntsville, Alabama + 164 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 16, 2026, 11:34 PM EDT
Completed Phase 3 Interventional Results available

A Study of PF-06438179 (Infliximab-Pfizer) and Infliximab in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis (REFLECTIONS B537-02).

NCT02222493
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
PF-06438179, Infliximab
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
43
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Peoria, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated May 30, 2018 · Synced Oct 16, 2026, 11:34 PM EDT
Withdrawn Not applicable Interventional

Infliximab, Regulatory T Cells, IL2 and Crohn's Disease

NCT01266785
View directory record Official record
Conditions
Crohn's Disease
Interventions
Infliximab
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 8, 2019 · Synced Oct 16, 2026, 11:34 PM EDT
Completed No phase listed Observational

A Long Term Safety Study of Infliximab (Remicade) in in Ulcerative Colitis Patients

NCT00207688
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Infliximab 5 mg/kg, Infliximab 10 mg/kg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
Not listed
Enrollment
505 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2015
U.S. locations
44
States / cities
Scottsdale, Arizona • Anaheim, California • Los Angeles, California + 41 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2018 · Synced Oct 16, 2026, 11:34 PM EDT
Completed Phase 1 Interventional Results available

Infliximab (Remicade) for Patients With Acute Kawasaki Disease

NCT00271570
View directory record Official record
Conditions
Kawasaki Disease
Interventions
Infliximab (Remicade), Intravenous immunoglobulin (IVIG)
Drug · Biological
Lead sponsor
University of California, San Diego
Other
Eligibility
Up to 18 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 14, 2010 · Synced Oct 16, 2026, 11:34 PM EDT
Completed Phase 4 Interventional Results available

Multi Center Prospective Registry of Infliximab Use for Childhood Uveitis

NCT00589628
View directory record Official record
Conditions
Chronic Uveitis
Interventions
infliximab
Drug
Lead sponsor
Egla C. Rabinovich
Other
Eligibility
4 Years to 18 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 26, 2013 · Synced Oct 16, 2026, 11:34 PM EDT
Recruiting Phase 3 Interventional

Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response

NCT03414502
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Methotrexate, Abatacept, Adalimumab, Azathioprine, Baricitinib, Certolizumab, Etanercept, Golimumab, Hydroxychloroquine, Infliximab, Leflunomide, Minocycline, Rituximab, Sarilumab, Sulfasalazine, Tofacitinib
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2029
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 16, 2026, 11:34 PM EDT